[170 Pages Report] The Rare Inflammatory Disease Treatment Market has garnered a market value of USD 12,664 Million in 2021, anticipated to register a positive CAGR of 4.6% in the forecast period 2022 to 2028 and reach a value of USD 17,335.8 Million.
| Attribute | Details |
|---|---|
| Rare Inflammatory Disease Treatment Market Size (2022) | USD 13,249.2 Million |
| Projected Market Value (2028) | USD 17,335.8 Million |
| Global Market Growth Rate (2022 to 2028) | 4.6% CAGR |
| Region With Dominant Market Share | North America |
Increasing investment in R&D for various drug developments and increasing demand for different modes of drug administration have further boosted the market demand for various rare inflammatory diseases treatments.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 8.35% |
| H1, 2022 Projected | 8.82% |
| H1, 2022 Outlook | 8.52% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 30 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (+) 17 ↑ |
A comparative analysis related to the market growth rates and development prospects in the global rare inflammatory disease treatment market is presented by Future Market Insights. The market is highly influenced by the onerous regulatory environment and innovation factors for orphan drugs under the impact of macro and industry factors.
According to Future Market Insights analysis, the global rare inflammatory disease treatment market expects to surge by 17 Basis Point Share (BPS) in H1-2022 as compared to H1- 2021. Whereas in comparison to H1-2022 projected value, the market during H1-2022 outlook period will show a dip of 30 BPS.
The market change in the BPS is associated with the extensive process of orphan drug approval by regulatory bodies for licensure and distribution. Further, revision in molecular portfolio for existing products also face a backlash in terms of patent renewal, owed to the emergence of several clinically viable alternatives to existing solutions.
This has caused a reduction in the BPS value. Additionally, the growth of the biopharmaceutical industry upon the advent of the COVID-19 pandemic has provided a boost in the BPS value change for the market.
The market is subject to activities such as supporting the treatment of rare diseases through collaborative activities, revenue fluidity which arises from product Medicaid rebates, chargebacks due to other government programs, and existing patented product portfolio.
From 2013 to 2021, treatment for rare inflammatory diseases experienced an increase of 3.8% in value CAGR terms. Various distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies have observed high demand for treating several rare inflammatory diseases. Recent outbreaks of infectious diseases, such as COVID-19, have increased market demand to a major extent.
During the height of the pandemic crisis, clinicians, doctors and other healthcare stakeholders extensively relied on anti-inflammatory drugs to ease complications experienced by severely infected and immunocompromised patients. Drugs such as ibuprofen, for instance, was cleared by the National Health Service in the U.K to be used as a nonsteroidal anti-inflammatory drug (NSAID) to inhibit receptors responsible for triggering an inflammatory response to the coronavirus.
Companies have been considering in their production processes ways to improve the treatment of rare inflammatory diseases, such as eosinophilic granulomatosis with polyangiitis (EGPA), a rare disorder that causes vasculitis. One such treatment is Nucala, a medication for patients aged 6 years or older with relapsing-remitting or refractory EGPA. Likewise, several orphan drugs are coming into the limelight for numerous rare inflammatory diseases. Overall, demand for rare inflammatory disease treatment is anticipated to rise at a CAGR of around 4.6% through 2028.
Principal Consultant
Healthcare experts have associated cytokine IL-23 with treatment of inflammatory and autoimmune diseases. Researchers have identified a fundamental molecular mechanism essential to inflammatory and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. The action of pro-inflammatory cytokine IL-23, depends on the organizational stimulation of its receptor, namely IL-23R.
Moreover, the occurrence of inflammatory and autoimmune diseases is increasing at a rapid pace. According to the World Health Organization, psoriasis affects approximately 100 million people globally, while between 1.3% and 34.7% develop chronic and inflammatory arthritis. Likewise, inflammatory bowel infections such as ulcerative colitis and Crohn’s disease are increasing at an alarming rate in formerly unaffected fragments of the world.
Hence, medical practitioners are introducing several drug candidates to address some of the most debilitating rare inflammatory diseases. In 2018, for instance, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) granted an extension of indication to Kineret (anakinra) for treating Still's disease. Kineret is an immunosuppressive medicine which inhibits chemical messenger activity of interleukin-1, an agent which is produced in excess amongst patients suffering from rheumatoid arthritis and juvenile idiopathic arthritis.
FMI forecasts the rare inflammatory disease treatment industry in North America to accumulate a market share of 39.9% in 2022. The presence of a well-developed health care system and several reimbursement programs aimed at facilitating access to treatment for those with rare illnesses are among the chief growth drivers.
More than 30 million Americans are afflicted with rare diseases. Every year, approximately 6,200 Americans are affected diseases, including Polycythemia Vera, while juvenile rheumatoid arthritis is one of the most common types of arthritic diseases that children are diagnosed with in the United States.
Demand for rare inflammatory disease treatment has risen through various distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies. As a result, the U.S. is expected to account for the largest market share in the market for rare inflammatory diseases treatment.
D of new treatments and advancements in medical technology have driven market demand for rare inflammatory disease treatment throughout Europe. With increasing investments in open-source drug delivery systems and evaluations of their effectiveness in treating rare diseases, more treatment options are becoming available for rare inflammatory diseases.
Recently, in September 2021, the European Medicines Agency has recommended granting an extension of indication to Nucala (mepolizumab) as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA), responsible for inflaming vital organs such as the lungs, heart, skin, nervous system and gastrointestinal tract.
It is estimated that between 0.18 and 4 new cases per 1 million are diagnosed each year with EGPA. The drug is already approved for treating patients of the same age group for eosinophilic asthma. According to FMI, rare inflammatory disease treatment in Europe is like to accumulate a market share of 24% in 2022.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Due to the significant cost savings associated with ulcerative colitis treatments, the producers will be influenced to increase their manufacturing capacities for advanced drugs and therapies in the future.
Technological advancements and the increasing number of patients suffering from ulcerative colitis have contributed to the development of advanced treatments for ulcerative colitis. The influx of new therapeutics methods, demand for enhancing drugs, and advances in treating ulcerative colitis have propelled market demand for rare inflammatory diseases treatments.
The growing prevalence of diseases and demand for 24/7 medication sales have catalyzed the global market demand for drugs at retail pharmacies. Future growth in artificial intelligence, advanced analytics, and other technologies will help drive the retail pharmacy market in the global market.
Health and wellness services are the key drivers of customer satisfaction at brick-and-mortar pharmacies. These services score 66 points higher than other types of services. Pharmacies with these services are present in 86% of chain pharmacies, 83% of supermarkets, and 75% of mass merchandisers.
Prominent treatment providers are emphasizing on advancing drug and treatment offerings by initiating a series of clinical studies as well as forging collaborative and acquisition agreements with existing pharmaceutical companies.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, India, Malaysia, Singapore, Australia, New Zealand, Israel, South Africa, GCC |
| Key Market Segments Covered | Indication, Drug Class, Mode of Administration, Distribution Channel |
| Key Companies Profiled | Novartis AG; Abbvie Inc.; Abbott Laboratories; Regeneron Pharmaceuticals Inc.; Swedish Orphan Biovitrum AB; Pfizer, Inc.; Valeant Pharmaceutical International Inc. (Bausch Health); Mallinckrodt Plc.; Johnson & Johnson |
| Pricing | Available upon Request |
In 2022, the global rare inflammatory disease treatment market is set to be net USD 13,249.2 Mn.
FMI Analysts predict the rare inflammatory disease treatment market to attain an estimated worth of USD 17,335.8 Mn by 2028
North America will hold the highest global market share of 39.9% in 2022
The rare inflammatory disease treatment industry to rise at a CAGR of 4.6% from 2022 to 2028
1. Global Economic Outlook 2. Global Rare Inflammatory Disease Treatment Market - Executive Summary 3. Global Rare Inflammatory Disease Treatment Market Overview 4. Global Rare Inflammatory Disease Treatment Market Analysis and Forecast 2013-2028 5. North America Rare Inflammatory Disease Treatment Market Size and Forecast, 2013-2028 6. Latin America Rare Inflammatory Disease Treatment Market Size and Forecast, 2013-2028 7. Europe Rare Inflammatory Disease Treatment Market Size and Forecast, 2013-2028 8. Japan Rare Inflammatory Disease Treatment Market Size and Forecast, 2013-2028 9. APEJ Rare Inflammatory Disease Treatment Market Size and Forecast, 2013-2028 10. MEA Rare Inflammatory Disease Treatment Market Size and Forecast, 2013-2028 11. Global Rare Inflammatory Disease Treatment Market Company Share, Competition Landscape and Company Profiles 11.1. Pfizer, Inc. 11.2. Novartis AG 11.3. Allergan Plc 11.4. Abbvie, Inc. 11.5. Valeant Pharmaceuticals International, Inc. 11.6. Abbott Laboratories 11.7. Johnson & Johnson 11.8. Regeneron Pharmaceuticals, Inc. 11.9. Mallinckrodt Plc 11.10. Swedish Orphan Biovitrum AB 12. Global Rare Inflammatory Disease Treatment Market - Key Takeaways 13. Research Methodology 14. Disclaimer
Explore Healthcare Insights
View Reports
Rare Inflammatory Disease Treatment Market
